Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

Sector: Healthcare Industry: Biotechnology CIK: 0001783183
P/B -2.51
P/E -3.86
P/S 7.20
Market Cap 1.06 Bn
ROIC (Qtr) -150.66
Div Yield % 0.00
Rev 1y % (Qtr) 202.74
Total Debt (Qtr) 558.79 Mn
Debt/Equity (Qtr) -1.32

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 138.02M provide 233.53x coverage of short-term debt 591000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong cash position of 138.02M provides 1.51x coverage of other current liabilities 91.46M, indicating excellent liquidity.
  • Cash reserves of 138.02M provide robust 1.48x coverage of current liabilities 93.12M, indicating strong short-term solvency.
  • Retained earnings of (1.46B) represent substantial 3.46x of equity (422.53M), indicating strong internal capital generation.
  • Cash reserves of 138.02M exceed inventory value of 27.71M by 4.98x, indicating strong liquidity and inventory management.

Cons

  • Investment activities of (147000) provide weak support for R&D spending of 33.87M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (225.23M) shows concerning coverage of stock compensation expenses of 29.80M, with a -7.56 ratio indicating potential earnings quality issues.
  • Free cash flow of (225.38M) provides weak coverage of capital expenditures of 147000, with a -1533.18 ratio suggesting additional external financing needs for growth initiatives.
  • High receivables of 55.79M relative to inventory of 27.71M (2.01 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • Operating earnings of (204.26M) show weak coverage of depreciation charges of 698000, with a -292.64 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 6.08 12.31
EV to Cash from Ops. -6.49 23.25
EV to Debt 2.61 738.44
EV to EBIT -7.15 -9.16
EV to EBITDA -6.87 6.95
EV to Free Cash Flow [EV/FCF] -6.48 21.90
EV to Market Cap 1.38 65.67
EV to Revenue 9.93 227.32
Price to Book Value [P/B] -2.51 22.34
Price to Earnings [P/E] -3.86 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -2.91 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 75.70 -27.13
Cash and Equivalents Growth (1y) % -59.11 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 25.18 -46.93
EBITDA Growth (1y) % 25.90 -1.68
EBIT Growth (1y) % 25.18 -56.45
EBT Growth (1y) % 19.12 -12.70
EPS Growth (1y) % 34.43 -28.31
FCF Growth (1y) % 9.02 -31.90
Gross Profit Growth (1y) % 485.20 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.61 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 1.48 3.85
Current Ratio 2.23 7.27
Debt to Equity Ratio -1.32 0.40
Interest Cover Ratio -2.91 841.00
Times Interest Earned -2.91 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -138.30 -18,234.31
EBIT Margin % -138.77 -18,580.80
EBT Margin % -186.53 -19,488.74
Gross Margin % 87.20 -7.59
Net Profit Margin % -186.50 -19,439.22